Age-specific differences in non-cardiac comorbidities among elderly patients hospitalized with heart failure: a special focus on young-old, old-old, and oldest-old

Meng-Xi Yang¹, Hui An², Xue-Qiang Fan³, Li-Yuan Tao⁴, Qiang Tu⁵, Li Qin⁷, Li-Fang Zhang¹, Dong-Ping Feng¹, Yu Wang¹, Li Sun¹, Si Gao¹, Wen-Zhuo Guan¹, Jin-Gang Zheng¹, Jing-Yi Ren¹

¹Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China; ²Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China; ³Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China; ⁴Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100029, China; ⁵State Key Laboratory for Molecular and Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China; ⁶University of Chinese Academy of Sciences, Beijing 100039, China; ⁷Department of Laboratory Medicine, Peking University People’s Hospital, Beijing 100044, China.

Abstract
Background: Despite the growing epidemic of heart failure (HF), there is limited data available to systematically compare non-cardiac comorbidities in the young-old, old-old, and oldest-old patients hospitalized for HF. The precise differences will add valuable information for better management of HF in elderly patients.
Methods: A total of 1053 patients aged 65 years or older hospitalized with HF were included in this study. Patients were compared among three age groups: (1) young-old: 65 to 74 years, (2) old-old: 75 to 84 years, and (3) oldest-old: ≥85 years. Clinical details of presentation, comorbidities, and prescribed medications were recorded.
Results: The mean age was 76.7 years and 12.7% were 85 years or older. Most elderly patients with HF (97.5%) had at least one of the non-cardiac comorbidities. The patterns of common non-cardiac comorbidities were different between the young-old and oldest-old group. The three most common non-cardiac comorbidities were anemia (53.6%), hyperlipidemia (45.9%), and diabetes (42.4%) in the young-old group, while anemia (73.1%), infection (58.2%), and chronic kidney disease (44.0%) in the oldest-old group. Polypharmacy was observed in 93.0% elderly patients with HF. Additionally, 29.2% patients were diagnosed with infection, and 67.0% patients were prescribed antibiotics. However, 60.4% patients were diagnosed with anemia with only 8.9% of them receiving iron repletion.
Conclusions: Non-cardiac comorbidities are nearly universal in three groups but obviously differ by age, and inappropriate medications are very common in elderly patients with HF. Further treatment strategies should be focused on providing optimal medications for age-specific non-cardiac conditions.
Keywords: Heart failure; Elderly; Non-cardiac comorbidity; Polypharmacy

Introduction
Heart failure (HF) is a major public health problem, primarily because of the aging of the population. Its prevalence has doubled from 6% in those aged from 60 to 79 years to approximately 14% in those aged 80 years or older. HF rarely occurs in isolation or represents a single maladaptive process that affects elderly patients. Cardiac and non-cardiac comorbidities, polypharmacy, and geriatric conditions all contribute to the health outcomes of elderly patients with HF. These factors and their complex interplay are essential aspects in older patients with important implications on management and prognosis. Thus, unlike the general population, clinicians caring for elderly patients with HF must consider all factors mentioned above in addition to the evaluation of the etiology, stage, and chronicity of HF.

Although there is a perception that elderly patients hospitalized for HF are becoming more medically complex, and non-cardiac comorbidities and inappropriate...
ate treatment differ by age in elderly patients with HF, there is a lack of evidence on the precise differences among young-old, old-old, and oldest-old patients in non-cardiac comorbidities and medication regimens. Therefore, a comprehensive and multidimensional assessment of elderly patients with HF in different age groups is essential for optimizing clinical management and treatment decision making.

To address the major issues mentioned above, this study had two objectives. The first was to give a comprehensive assessment of non-cardiac conditions among elderly patients with HF stratified by age, which are frequently overlooked during routine HF management. The second objective was to compare the medication regimen complexity in different age groups, including the number of medications, potentially inappropriate medications for non-cardiac conditions, and the use of guideline-directed therapies.

Methods

Ethical approval

This study was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2019-83-k54). Given its retrospective nature and the fact that data analysis was performed anonymously, it was exempt from obtaining informed consent from patients.

Study population

This was a real-world research at the Heart Failure Center in China-Japan Friendship Hospital. Patients admitted to hospital and aged 65 years or older were recruited consecutively between January 1, 2013, and December 31, 2017. The diagnosis of HF (new-onset HF or decompensation of chronic HF) was determined according to the clinical practice guidelines by the Chinese Society of Cardiology and was briefly based on: (1) symptoms, for example, dyspnea, fatigue, or decreased exercise capacity; (2) signs, for example, edema or rales; (3) B type natriuretic peptide or N-terminal pro-B type natriuretic peptide; to differentiate the HF diagnosis for patients with dyspnea; (4) structural and functional abnormalities on echocardiography.

A total of 1053 patients were enrolled for further analysis. They were categorized as three groups according to their age: (1) young-old: 65 to 74 years (n = 401), (2) old-old: 75 to 84 years (n = 518), and (3) oldest-old: ≥85 years (n = 134).

Data collection

For patients hospitalized with HF, clinical details of presentation (eg, demographics, echocardiographic, and biochemical data) at admission and discharge were recorded.

We also extracted information about comorbidities. Because all patients had HF, this condition was not considered a comorbidity. To describe comorbidities, we categorized comorbidities as cardiac and non-cardiac. Cardiac comorbidities were defined as any of the following: coronary heart disease, hypertension, atrial fibrillation, cardiomyopathy, and valvular disorders. To describe non-cardiac comorbidities, we selected 13 most common conditions: anemia, diabetes, chronic kidney disease (CKD), stroke, dyslipidemia, infection, chronic obstructive pulmonary disease (COPD) or asthma, cancer, osteoporosis, sleep apnea, thyroid disease, depression, and cognitive impairment. For each condition, we reported prevalence as the percentage of patients with a diagnosis recorded in their hospital discharge record. Patients without a diagnosis were assumed to be free from that condition.

Admission and discharge medications details were collected, including guideline-directed medications (eg, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], β-blockers, and mineralocorticoid receptor antagonists [MRAs]), symptomatic relieved medications (eg, diuretics, digitalis, nitrates), and other prescription medications (eg, iron repletion, antibiotic, anti-platelet, oral anti-coagulant etc). The number of co-administered medications of every patient was counted. Polypharmacy was defined as the use of at least 5 co-administered medications.

Statistical analysis

Data are presented as frequencies (%) for categorical data, means, and standard deviation for normally distributed continuous variables, or medians and interquartile range for non-normally distributed continuous variables. Comparisons were performed by analysis of variance and followed up with a post hoc Bonferroni test for symmetrical continuous, Mann-Whitney U or Kruskal-Wallis H test for non-symmetric continuous, and χ² tests or Continuity correction or Fisher exact test for categorical variables. All P < 0.05 from two-sided tests were accepted as statistically significant. All statistical analyses were performed using SPSS 23.0 software (SPSS Inc., Chicago, IL, USA).

Results

Characteristics of elderly patients hospitalized with HF

A total of 1053 elderly patients hospitalized with HF were included in the present analysis. Demographic, echocardiographic, and biochemical data on the three groups were given in Table 1 and Table S1, http://links.lww.com/CM9/A132. The mean age was 76.7 ± 6.6 years and 52.9% were male. There were 401 (38.1%) young-old patients (median age 70.0 years), 518 (49.2%) old-old patients (median age 79.1 years), and 134 (12.7%) oldest-old patients (median age 87.7 years). Age distribution of elderly patients hospitalized with HF was given in Figure S1, http://links.lww.com/CM9/A130.

Elderly patients with HF were inclined to unplanned admissions with age, and the emergency admission proportion in the oldest-old group was up to 41.0%, nearly doubled compared with the young-old group.
Values are mean ± standard deviation or number (%) unless indicated otherwise. Median [interquartile range]. * Significant difference compared with the young-old group (P < 0.025). BMI: Body mass index; underweight defined as BMI < 18.5 kg/m²; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BNP: B-type natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; eGFR: Estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction.

(P < 0.001). The median hospital length of stay was longest in the oldest-old group (18 days), and the shortest in the young-old group (15 days) (P = 0.004).

Cardiac and non-cardiac comorbidities of elderly patients hospitalized with HF

The elderly patients with HF typically have extensive comorbidities with the number ranged from 0 to 11. Overall, 97.1% of the elderly patients with HF had two or more additional conditions [Table 2]. Not surprisingly, the number of comorbidities in the elderly patients with HF was increased with age [Figure 1A].

The burden of non-cardiac comorbidity was obviously greater than that of cardiac comorbidity in all the three groups [Figure 1B]. It is noteworthy that the number of individual non-cardiac comorbidities was increased with age; the oldest-old group had a higher prevalence of ≥3 non-cardiac morbidities (68.7% vs. 65.8% and 53.1%) compared with the old-old and the young-old group, respectively (P < 0.001).

The common non-cardiac comorbidity patterns among the three groups were different [Figure 1C and 1D]. The three most common non-cardiac comorbidities in the young-old group were anemia (53.6%), hyperlipidemia (45.9%), and diabetes (42.4%). While in the oldest-old group, the three most common non-cardiac comorbidities were anemia (73.1%), infection (58.2%), and CKD (44.0%).

A total of 60.4% elderly patients with HF had anemia which was the highest represented non-cardiac comorbidity in all the three groups. Almost three-quarters of the oldest-old patients with HF had anemia, but less than 1% measured the serum ferritin to diagnose iron deficiency. A dramatical increase in the prevalence of infection with age was observed, doubling in prevalence from 29.2% in the young-old group to 58.2% in the oldest-old group (P < 0.001). In addition, the average prevalence of stroke was 26.8%, with a significant increase in the oldest-old group, nearly twice higher compared with the young-old group (35.1% vs. 19.0%, P < 0.001). Besides, the prevalence of CKD, COPD or asthma, cancer, and osteoporosis was also greatly increased from the young-old to the oldest-old groups (all P < 0.05) [Table 2 and Figure 1C].

Medications at admission and discharge of the elderly patients hospitalized with HF

Prescribed medications among three groups were given in Table 3 and Table S2, http://links.lww.com/CM9/A133. On average, the elderly patients with HF take 9.4 prescription medications per day, not including over-the-counter or complementary and alternative medications. The number of medications prescribed was increased with age. Polypharmacy (≥5 medications) occurred in 93.0% of the elderly patients with HF and 43.0% of them was prescribed at least ten medications. The proportion of the elderly patients prescribed at least ten medications was approaching twice higher in the oldest-old group compared with that in the young-old group (65.7% vs. 33.7%, P < 0.01). Of note, there were 5 (3.7%) patients in the oldest-old group taking 20 or more medications.

Additionally, underuse and overuse of medications were very common in the elderly patients with HF [Figure 2]. The overuse of medications was mainly observed for
In this study, we evaluated age-specific clinical profile, cardiac and non-cardiac comorbidities, and medication regimens among elderly patients hospitalized with HF. Our analysis identified that, unlike the general population, the burden of non-cardiac comorbidities was noticeably greater in elderly patients with HF compared with that of cardiac comorbidities, and the prevalence of these conditions particularly increased with age. Interestingly, the patterns of the most common non-cardiac comorbidities were apparently different between the young-old and oldest-old patients with HF. The presence of anemia, infection, CKD, and stroke was more common in the oldest-old patients. However, the frequency of dyslipidemia and diabetes was higher in the young-old patients. To our knowledge, this has not been adequately investigated in the previous studies. Our findings also confirmed that polypharmacy and inappropriate medications have increased dramatically in the elderly patients, especially in the oldest-old. Additionally, administration of unnecessary antibiotics for infection and inadequate administration of iron repletion for anemia were the most frequent inappropriate therapies. Our study complements the knowledge in regard to age-related changes in the clinical features among elderly patients hospitalized with HF.

Our study showed that the burden of non-cardiac comorbidities in elderly patients hospitalized with HF, particularly in the oldest-old patients, was greater than that of cardiac comorbidities. We observed that, among elderly patients, HF without non-cardiac comorbidities is very rare, occurring in only 2.5% of the patients and more than 60% of the elderly patients have three or more non-cardiac comorbidities. Our analysis was consistent with the prior studies which have identified that patients with HF have a large burden of non-cardiac comorbidities.

There was an inadequacy of guideline-directed HF medications in elderly patients with HF at admission [Table 3], especially in the oldest-old group; ACE inhibitors/ARBs, β-blockers, and MRAs were prescribed in the lowest rate of 39.8%, 53.0%, and 38.8%, respectively. Indeed, few patients appear to receive all the three medications simultaneously. There was an apparent further decrease of discharge medications in comparison with admission medications [Figure S2, http://links.lww.com/CM9/A131].

**Discussion**

In this study, we evaluated age-specific clinical profile, cardiac and non-cardiac comorbidities, and medication regimens among elderly patients hospitalized with HF. Our analysis identified that, unlike the general population, the burden of non-cardiac comorbidities was noticeably greater in elderly patients with HF compared with that of cardiac comorbidities, and the prevalence of these conditions particularly increased with age. Interestingly, the patterns of the most common non-cardiac comorbidities were apparently different between the young-old and oldest-old patients with HF. The presence of anemia, infection, CKD, and stroke was more common in the oldest-old patients. However, the frequency of dyslipidemia and diabetes was higher in the young-old patients. To our knowledge, this has not been adequately investigated in the previous studies. Our findings also confirmed that polypharmacy and inappropriate medications have increased dramatically in the elderly patients, especially in the oldest-old. Additionally, administration of unnecessary antibiotics for infection and inadequate administration of iron repletion for anemia were the most frequent inappropriate therapies. Our study complements the knowledge in regard to age-related changes in the clinical features among elderly patients hospitalized with HF.

Our study showed that the burden of non-cardiac comorbidities in elderly patients hospitalized with HF, particularly in the oldest-old patients, was greater than that of cardiac comorbidities. We observed that, among elderly patients, HF without non-cardiac comorbidities is very rare, occurring in only 2.5% of the patients and more than 60% of the elderly patients have three or more non-cardiac comorbidities. Our analysis was consistent with the prior studies which have identified that patients with HF have a large burden of non-cardiac comorbidities.
comorbidities.\cite{16,17} According to the Get With The Guidelines-Heart Failure Registry, among patients admitted to hospital for HF, 82\% had at least one non-cardiac comorbidity.\cite{16} In the European Society of Cardiology HF Pilot survey, it was shown that the majority of patients (74\%) with chronic HF had at least one of the non-cardiac comorbidities.\cite{16}

The previous studies mainly focused on the comparison of the clinical features of HF between older and younger...
patients with HF, or between patients <75 years and those ≥75 years. Our results identified that patients ≥85 years were obviously different from the young-old patients, even from those aged 75 to 84 years, with respect to the non-cardiac comorbidities. The oldest-old patients appear to be less likely to have traditional risk factors such as diabetes and dyslipidemia, as compared with the young-old patients. Anemia, infection, CKD, and stroke were the most common non-cardiac conditions in these patients. Accordingly, our results suggest that routine risk factors intervention was needed for the young-old patients; however, other non-cardiac conditions management such

| Table 3: Medications at admission and discharge of elderly patients hospitalized with HF by age group. |
|-----------------------------------------|----------------|----------------|----------------|----------------|----------------|
| Indices                                | Total n = 1053 | Young-old (65–74 years), n = 401 (38.1%) | Old-old (75–84 years), n = 518 (49.2%) | Oldest-old (≥85 years), n = 134 (12.7%) | P value |
| Admission medications                  |               |               |               |               |                 |
| ACE-inhibitors/ARBs                    | 620 (59.0)    | 248 (62.2)    | 319 (61.6)    | 53 (39.8)      | <0.001          |
| β-Blockers                             | 678 (64.4)    | 281 (70.1)    | 326 (62.9)    | 71 (53.0)      | 0.001           |
| MRAs                                   | 436 (41.4)    | 184 (45.9)    | 200 (38.6)    | 52 (38.8)      | 0.069           |
| Diuretics                              | 847 (80.4)    | 324 (80.8)    | 403 (77.8)    | 120 (89.6)     | 0.009           |
| Digitalis                              | 452 (42.9)    | 186 (46.4)    | 203 (39.2)    | 63 (47.0)      | 0.054           |
| Nitrites                                | 855 (81.2)    | 319 (79.6)    | 420 (81.1)    | 116 (86.6)     | 0.197           |
| Anti-platelet                          | 713 (67.7)    | 261 (65.1)    | 370 (71.4)    | 82 (61.2)      | 0.028           |
| Anti-coagulant                         | 163 (15.5)    | 73 (18.2)     | 74 (14.3)     | 16 (11.9)      | 0.127           |
| Statins                                 | 501 (47.6)    | 195 (48.6)    | 265 (51.2)    | 41 (30.6)      | <0.001          |
| CCB                                     | 407 (38.7)    | 136 (33.9)    | 223 (43.1)    | 48 (35.8)      | 0.014           |
| Iron repletion                         | 94 (8.9)      | 24 (6.0)      | 48 (9.3)      | 22 (16.4)      | 0.001           |
| Antibiotic                              | 706 (67.0)    | 260 (64.8)    | 337 (65.1)    | 109 (81.3)     | 0.001           |
| Discharge medications                  |               |               |               |               |                 |
| ACE-inhibitors/ARBs                    | 464 (44.1)    | 181 (45.1)    | 249 (48.1)    | 34 (25.4)      | <0.001          |
| β-Blockers                             | 529 (50.3)    | 226 (56.5)    | 262 (50.6)    | 41 (30.8)      | <0.001          |
| MRAs                                   | 300 (28.5)    | 121 (30.2)    | 142 (27.4)    | 37 (27.6)      | 0.636           |
| Diuretics                              | 507 (48.1)    | 211 (52.6)    | 239 (46.1)    | 57 (42.5)      | 0.057           |
| Digitalis                              | 193 (18.3)    | 84 (20.9)     | 88 (17.0)     | 21 (15.7)      | 0.213           |
| Nitrites                                | 508 (48.2)    | 193 (48.1)    | 258 (49.8)    | 57 (42.5)      | 0.324           |
| Anti-platelet                          | 541 (51.4)    | 201 (50.1)    | 285 (55.0)    | 55 (41.0)      | 0.013           |
| Anti-coagulant                         | 163 (15.5)    | 73 (18.2)     | 74 (14.3)     | 16 (11.9)      | 0.127           |
| Statins                                 | 442 (42.0)    | 175 (43.6)    | 234 (45.2)    | 33 (24.6)      | <0.001          |
| CCB                                     | 306 (29.1)    | 109 (27.2)    | 162 (31.3)    | 35 (26.1)      | 0.289           |
| Iron repletion                         | 72 (6.8)      | 20 (5.0)      | 36 (6.9)      | 16 (11.9)      | 0.022           |
| Number of medications                  | 9.4 ± 4.0     | 8.7 ± 3.6     | 9.7 ± 4.2     | 10.3 ± 4.0     | 0.001           |
| ≥5                                     | 979 (93.0)    | 366 (91.3)    | 483 (93.2)    | 130 (97.0)     | 0.154           |
| ≥10                                    | 453 (43.0)    | 135 (33.7)    | 243 (46.9)    | 88 (65.7)      | <0.001          |

Values are mean ± standard deviation or n [%]. * Significant difference compared with the young-old group (P < 0.025). ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; CCB: Calcium channel blocker; MRAs: Mineralocorticoid receptor antagonists.

Figure 2: Non-cardiac comorbidities and medications of elderly patients hospitalized with HF by age group. (A) Infection diagnosed and antibiotic prescribed in patients with HF. (B) Anemia diagnosed and iron repletion prescribed in patients with HF. HF: Heart failure; y: Years.
as conservation of renal function and infection prevention was more important for the oldest-old patients.

In our study, more than 60% of the elderly patients were diagnosed with HF combined with anemia, which was higher than that in the previous surveys and registries with a range of 22% to 47%. An increase of anemia prevalence with age was observed in our analysis and was supported by the recent studies. Nearly two-thirds of the subjects were over 75 years in the current survey, which may partly explain higher anemia prevalence in the study. The results may also be associated with the poor clinical status (eg, hospitalized of decompensation HF) and malnutrition (eg, lower body mass index and albumin level) in our study population. As confirmed previously, compared with non-anemic patients with HF, anemic patients are more likely to have CKD, severe HF with worse functional status, lower exercise capacity, and increased mortality. Therefore, anemia in elderly patients with HF, especially in the oldest-old, should definitely be taken seriously.

Stroke is the most common cause of disability in adult life and a major cause of death in China. As an important non-cardiac comorbidity in the present study, the prevalence of stroke in elderly patients with HF was 26.8%, and up to 35.1% in the oldest-old adults, which was five- to six-fold compared with the general elderly population (5.2%) in China. The prevalence of stroke was also noticeably higher than the previous trials conducted in western countries (7%–10%). The observed results in high stroke prevalence may be associated with the fact that the heart and the brain share many pathophysiological mechanisms, such as atherosclerotic and thrombotic processes, which lead to acute damage and/or chronic organ dysfunction. But more likely, it was due to the current stroke incidence and mortality rates in China, which appear to be the highest in the world. Stroke sequelae worsen performance status and quality of life, which in turn substantially contributes to mortality in HF patients. This finding highlights the importance of clinical attention to stroke among elderly HF patients, and further studies on potential prevention strategies are warranted.

In accordance with the previous studies, polypharmacy was nearly universal in elderly patients with HF, especially among the oldest-old patients with a multimorbidity burden. Our study showed that polypharmacy existed in more than 90% of elderly patients with HF, with 65.7% of the oldest-old patients with HF prescribed with at least ten medications, and 3.7% were even prescribed with more than 20 medications.

In addition to polypharmacy, inappropriate treatment was another profound problem in the management of HF among elderly patients. For instance, infection was one of the main precipitating factors leading to HF admissions. As a result, broad-spectrum antibiotic prescriptions were common. In the present study, approximately 67.0% of the patients with HF were treated with antibiotics; however, only 40.3% have concomitant infection. Although our results of infection were more common compared with the previous surveys and registries both in Europe and the USA with a range of 10% to 21%, routine use of empirical antibiotics in patients with HF was exacerbated in the absence of convincing evidence of infection. Previous studies provided evidence for the potentially harmful effects of antibiotics, particularly promoting anti-microbial resistance and life-threatening events, when used indiscriminately in clinically symptomatic HF patients without underlying infection. The problem of administration of unnecessary antibiotics appeared to be even worse in the oldest-old patients than in the other two groups. The oldest-old patients got more infections (58.2%) and received more antibiotics (81.3%). Reasons for antibiotic overuse in the oldest-old patients are myriad, including diagnostic uncertainty, physicians’ desire for an improved outcome, treatment of conditions caused by colonizing or contaminating organisms, and concern for bacterial superinfection, suggesting that infection indicators (eg, neutrophils, procalcitonin) should be used to exclude bacterial infection and guide antibiotic treatment in oldest-old patients suspicion for infection.

In contrast to the overuse of antibiotics, treatment of anemia was extremely rare in our study, despite the high prevalence. Anemia in the elderly patients is often iron deficiency anemia because of inadequate iron intake and absorption disorders. In our study, approximately three-quarters of the oldest-old patients were with anemia, whereas less than 1% of the patients took serum ferritin detection and a significantly lower proportion of the patients (16.4%) were prescribed with an iron repletion than expected, suggesting that iron deficiency inspection and iron repletion is generally ignored during the management of patients with HF, especially among the oldest-old patients. These results were largely due to the lack of recommendations about screening and treatments for iron deficiency in the previous Chinese HF guideline, making clinicians pay less attention to iron deficiency. Elderly patients with HF are at increased risk for anemia and iron deficiency, and should, therefore, be screened for ferritin and transferrin saturation and be prescribed iron repletion accordingly. Iron replacement is appropriate in patients with anemia resulting from iron deficiency, especially in oldest-old patients to improves symptoms and exercise capacity.

There were several limitations in this study. First, although our results showed a significant difference in the clinical features among elderly patients with HF among different age groups, due to the cross-sectional nature, we were unable to analyze the effect of these differences on the outcomes of HF. Second, there was growing recognition that geriatric conditions such as disability, cognitive impairment, and frailty were essential and affect the management and outcome of elderly patients with HF. Unfortunately, these geriatric conditions were not adequately assessed in our study. Finally, despite a single-center study, a comprehensive assessment of clinical features (eg, symptoms, signs, comorbidities), hemodynamics, imaging including echocardiography, and treatment was available in our study; hence, we were able to provide more detailed information and to identify HF more accurately than International Classification of
Diseases, 9th Revision, making our study more representative of the elderly population with HF.

Conclusions

The results of our study demonstrated that the burden of non-cardiac comorbidities was nearly universal and obviously greater than that of cardiac comorbidities in elderly patients hospitalized with HF. Besides, the patterns of the non-cardiac comorbidities differed by age. The oldest-old patients appeared to be less likely to have traditional risk factors such as diabetes and dyslipidemia as seen in the young-old patients, while anemia, infection, CKD, and stroke were more common. Moreover, polypharmacy and inappropriately prescribed medications, especially on non-cardiac conditions (eg, administration of unnecessary antibiotics and inadequate administration of iron repletion), were very common in elderly patients. In this regard, a better understanding of the age-related differences of clinical features and more comprehensive care of non-cardiac comorbidities are vital for further improving prognosis in elderly patients with HF. We need more information on elderly patients with HF stratified by age in a large cohort to design preventive and therapeutic strategies specifically directed toward them.

Funding

This work was supported by the National Natural Science Foundation of China (81770359 and 81270276), Central Health Research Project of China (W2017J30), State Key Laboratory of Molecular Developmental Biology of China (2017-MDB-KF-13) to Jingyi Ren; and China-Japan Friendship Hospital Scientific Research Funds (2017-1-QN-10) to Mengxi Yang.

Conflicts of interest

None.

References

1. Cleland JG, van Veldhuisen DJ, Ponikowski P. The year in cardiology 2018: heart failure. Eur Heart J 2019;40:651–661. doi: 10.1093/eurheartj/ehz010.
2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018;137: e67–e492. doi: 10.1161/CIR.0000000000005538.
3. Chen YY, Chen Y, Liang SM, Su ZZ, Shu XR, Zhang HF, et al. Prognostic impact of fasting plasma glucose on mortality and re-hospitalization in patients with acute heart failure. Chin Med J 2018;131:2032–2040. doi: 10.4103/cmj.cmj_339_17.
4. Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail 2017;23:464–475. doi: 10.1016/j.cardfail.2017.04.007.
5. Manemann SM, Chamberlain AM, Boyd CM, Gerber Y, Dunlay SM, Weston SA, et al. Multimorbidity in heart failure: effect on outcomes. J Am Geriatr Soc 2016;64:1469–1474. doi: 10.1111/jgs.14206.
6. Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation 2013;127:1347–1355. doi: 10.1161/CIRCULATION- NAHA.111.014281.
7. Ather S, Chan W, Bokhurst B, Aguilar D, Ramassubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:1088–1098. doi: 10.1016/j.jacc.2009.08.040.
8. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226–1233. doi: 10.1016/s0140-6736(03)00947-1.
9. Gorodeski EZ, Goyal P, Hummel SL, Krishnaswami A, Goodlin SJ, Hart LL, et al. Domain management approach to heart failure in the geriatric patient: present and future. J Am Coll Cardiol 2018;71:1921–1936. doi: 10.1016/j.jacc.2018.02.059.
10. Kitzman DW, Rich MW. Age disparities in heart failure research. JAMA 2010;303:1950–1951. doi: 10.1001/jama.2010.1592.
11. Meng L, Shi H, Shi J, Yu P. Impact of comorbidities in older adults: characteristics, muscle mass, and physical performance among different frailty levels in Chinese older men. Chin Med J 2019;132:352–355. doi: 10.1097/CMI.0000000000000335.
12. Rich MW, Chyun DA, Skolnick AH, Alexander KP, Forman DE, Kitzman DW, et al. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. J Am Coll Cardiol 2016;67:2419–2440. doi: 10.1016/j.jacc.2016.03.004.
13. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2014 China guideline for diagnosis and treatment of heart failure (in Chinese). Chin J Cardiol 2014;42:98–121. doi: 10.3760/cma.jscc.0253–3758.2014.02.004.
14. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2010 China guideline for diagnosis and treatment of acute heart failure (in Chinese). Chin J Cardiol 2010;38:195–208. doi: 10.3969/j.issn.1672-7185.2013.14.001.
15. Qato DM, Alexander GC, Comr RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867–2878. doi: 10.1001/jama.2008.892.
16. Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, et al. Trends in noncardiac comorbidities among patients hospitalized for heart failure: insights from the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail 2018;11:e004646. doi: 10.1161/CIRCHEARTFAILURE.117.004646.
17. van Deursen VM, Urso R, Laroche C, Damman K, Dahlenstrom U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16:103–111. doi: 10.1002/ejhf.30.
18. Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, van Veldhuisen DJ, Hillege HL, et al. Knowledge gaps in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:486–496. doi: 10.1016/j.jacc.2007.05.039.
19. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespolillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018;391:572–580. doi: 10.1016/S0140-6736(17)32520-5.
20. Stauder R, Valentin P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood 2018;131:505–514. doi: 10.1182/blood-2017-07-746446.
21. Groenewald HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818–827. doi: 10.1016/j.jacc.2008.04.061.
22. Gattadoni G, Agostoni P, Corra U, van Wijngaarden DJ, Hillege HL, van Veldhuisen DJ, et al. Heart failure and anemia: effects on prognostic variables. Eur J Intern Med 2017;37:56–63. doi: 10.1016/j.ejim.2016.09.011.
23. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480687 adults. Circulation 2017;135:759–771. doi: 10.1161/CIRCULATIONAHA.116.025250.
24. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:215–237. doi: 10.1016/s0140-6736(13)61953-4.
25. Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007;49:963–971. doi: 10.1016/j.jacc.2006.10.059.

26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16:817–825. doi: 10.1002/ejhf.115.

27. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27–35. doi: 10.1161/CIRCHEARTFAILURE.109.932986.

28. Adelborg K, Szepligeti S, Sundboll J, Horvath-Puho E, Henderson VW, Ording A, et al. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 2017;48:1161–1168. doi: 10.1161/STROKEAHA.116.016022.

29. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011;124:136–143. doi: 10.1016/j.amjmed.2010.08.017.

30. Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002;4:91–98. doi: 10.1016/s1388-9842(01)00200-8.

31. Mo L, Dong D, Pu SY, Liu QH, Li H, Dong BR, et al. Patients aged 80 years or older are encountered more potentially inappropriate medication use. Chin Med J 2016;129:22–27. doi: 10.4103/0366-6999.172538.

32. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harijola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2723–2736. doi: 10.1093/eurheartj/ejh193.

33. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168:847–854. doi: 10.1001/archinte.168.8.847.

34. Schuetz P, Kutz A, Groolmundt E, Haubitz S, Demann D, Vogeli A, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014;175:464–472. doi: 10.1016/j.ijcard.2014.06.022.

35. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 2018;138:80–98. doi: 10.1161/CIRCULATIONAHA.118.030099.

36. Charles-Edwards G, Amaral N, Sleigh A, Ayss S, Cardhob N, McDonagh T, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency: the FERRIC-HF II randomized mechanistic trial. Circulation 2019;139:2386–2398. doi: 10.1161/CIRCULATIONAHA. 118.038516.

37. Rocha BML, Cunha GJL, Menezes Falcao LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol 2018;71:782–793. doi: 10.1016/j.jacc.2017.12.027.

38. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125–133. doi: 10.1002/ejhf.823.

39. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–668. doi: 10.1093/eurheartj/ehu385.

How to cite this article: Yang MX, An H, Fan XQ, Tao LY, Tu Q, Qin L, Zhang LF, Feng DP, Wang Y, Sun L, Gao S, Guan WZ, Zheng JG, Ren JY. Age-specific differences in non-cardiac comorbidities among elderly patients hospitalized with heart failure: a special focus on young-old, old-old, and oldest-old. Chin Med J 2019;132:2905–2913. doi: 10.1097/CM9.0000000000000560. 

Chinese Medical Journal 2019;132(24) www.cmj.org